Member Listing

Name

David Bedford

Title

Dr

Other Affiliation

Mission Therapeutics Ltd

Role

Other

Research Summary

Interested in targeting the key pathophysiological mechanisms that underpin Cardiovascular and Metabolic diseases, to discover and develop innovative medicines for the treatment of type 2 diabetes, diabetic nephropathy, cardiovascular disease and NASH.

I am also interested in better understanding the metabolic adaptation of renal proximal tubule epithelial cells to ischemia-reperfusion injury. More specifically, how these changes in metabolism are interconnected with cellular mechanisms regulating protein homeostasis and whether this knowledge can be exploited to develop novel therapies for the treatment or prevention of acute kidney injury.

Expertise

Biochemistry and Molecular Biology, Cell Biology, Other

Selected Publications

Enhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress.
Sci Reports 2018 Mar 2; 8(1)
Garner KL, Betin VMS, Pinto V, Graham M, Abgueguen E, Barnes M, Bedford DC, McArdle CA, Coward RJM.

Mutation of the CH1 Domain in the Histone Acetyltransferase CREBBP Results in Autism-Relevant Behaviours in Mice.
PLoS One 2016 Jan 5; 11(1).
Zheng F, Kasper LH, Bedford DC, Lerach S, Teubner BJ, Brindle PK.

Prox1 determines hepatocyte verus cholangiocyte fate choices in hepatoblasts.
Development 2014 Feb; 141(3):538-47.
Seth A, Bedford DC, Guez F, Kaestner K, Brindle PK, Sosa-Pineda B.

Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.
Cell Metabolism 2011 Aug 3;14(2):219-230.
Bedford DC, Kasper LH, Wang R, Chang Y, Green DR, Brindle PK.

S6K1: Reducing the RiSKs of aging.
Dis Model Mech. 2010 Mar-Apr;3(3-4):123-4.
Bedford DC.

Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases.
Epigenetics. 2010 Jan;5(1):9-15.
Bedford DC, Kasper LH, Fukuyama T, Brindle PK.

Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice.
Diabetologia. 2006 Mar; 49(3): 552-61.
Simmgen M, Knauf C, Lopez M, Choudhury AI, Charalambous M, Cantley J, Bedford DC, Claret M, Iglesias MA, Heffron H, Cani PD, Vidal-Puig A, Burcelin R, Withers DJ.

The role of insulin receptor substrate 2 in hypothalamic and beta cell function.
J Clin Invest. 2005 Apr; 115(4): 940-50.
Choudhury AI, Heffron H, Smith MA, Al-Qassab H, Xu AW, Selman C, Simmgen M, Clements M, Claret M, Maccoll G, Bedford DC, Hisadome K, Diakonov I, Moosajee V, Bell JD, Speakman JR, Batterham RL, Barsh GS, Ashford ML, Withers DJ.

High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells.
Anal Biochem. 2003 Sep 1; 320(1): 66-74.
Elaine Barrie S, Eno-Amooquaye E, Hardcastle A, Platt G, Richards J, Bedford D, Workman P, Aherne W, Mittnacht S, Garrett MD.

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
J Biol Chem. 2001 May 18; 276(20): 16617-23. Epub 2001 Feb 06.
Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD.

Other field of expertise

Drug Discovery